Dehydroglyasperin C

Name: Dehydroglyasperin C
Brand: MedChemExpress
SKU: HY-N7335
Rating: 4.5 (1 reviews)

Cat. No.: HY-N7335 Purity: 99.12%: FAQs
Data Sheet SDS COA Handling Instructions

Molarity Calculator

Dehydroglyasperin C, a isoflavone, is a potent NAD(P)H:oxidoquinone reductase (NQO1) and phase 2 enzyme inducer. Dehydroglyasperin C has antioxidant, neuroprotective, cancer chemopreventive, and anti-inflammatory activities.

For research use only. We do not sell to patients.

Dehydroglyasperin C Chemical Structure

CAS No. : 199331-35-6

Size	Price	Stock	Quantity
1 mg	USD 350	In-stock	Estimated Time of Arrival: December 31
5 mg	USD 1050	In-stock	Estimated Time of Arrival: December 31
10 mg		Get quote
50 mg		Get quote

or Bulk Inquiry

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 1 publication(s) in Google Scholar

Featured Recommendations

•Related Small Molecules:

•Related Proteins:

Biological Activity
Purity & Documentation
References
Customer Review

Description

Cellular Effect

Cell Line	Type	Value	Description	References
RAW264.7	IC₅₀	8.1 μM Compound: 53	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess assay	[PMID: 26841168]

In Vitro

Dehydroglyasperin C (0.1-1 μM; 24 h) blocks the PDGF-induced progression through the G0/G1 to S phase of the cell cycle, and down-regulates the expression of CDK; 2, cyclin E, CDK4 and cyclin D1. Dehydroglyasperin C significantly attenuates PDGF-stimulated phosphorylation of PDGF receptor-β, phospholipase C-γ1, AKT and extracellular-regulated kinase 1/2, and DGC inhibits cell migration and the dissociation of actin filaments by PDGF^[1].
Dehydroglyasperin C (0.1-1 μM; 24 h) treatment significantly decreases PDGF-induced cell number and DNA synthesis in a dose-dependent manner without any cytotoxicity in human aortic smooth muscle cells (HASMC)^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cycle Analysis^[1]

Cell Line:	Human aortic smooth muscle cells (HASMC)
Concentration:	0.1 μM, 0.5 μM, 1 μM
Incubation Time:	24 hours
Result:	Blocked the PDGF-induced progression through the G0/G1 to S phase of the cell cycle.

Western Blot Analysis^[1]

Cell Line:	Human aortic smooth muscle cells (HASMC)
Concentration:	0.1 μM, 0.5 μM, 1 μM
Incubation Time:	24 hours
Result:	Down-regulated the expression of CDK; 2, cyclin E, CDK4 and cyclin D1.

In Vivo

In ICR mice, Dehydroglyasperin C (5 mg/kg; once) combined with CCl4 shows reduced lipid droplet formation in liver tissue, as assessed by histological examination. Further, DGC demonstrated a slight protective effect against centrilobular injury caused by CCl4 injection, perhaps through suppression of CYP2E1 expression^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Molecular Weight

354.40

Formula

C₂₁H₂₂O₅

CAS No.

199331-35-6

Appearance

Solid

Color

White to off-white

SMILES

OC1=CC=C(C2=CC3=C(OC)C(C/C=C(C)\C)=C(O)C=C3OC2)C(O)=C1

Structure Classification

Initial Source

Shipping

Room temperature in continental US; may vary elsewhere.

Storage

4°C, protect from light

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

Solvent & Solubility

In Vitro:

DMSO : 100 mg/mL (282.17 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

Preparing
Stock Solutions

Concentration Solvent Mass	1 mg	5 mg	10 mg

1 mM	2.8217 mL	14.1084 mL	28.2167 mL
5 mM	0.5643 mL	2.8217 mL	5.6433 mL
10 mM	0.2822 mL	1.4108 mL	2.8217 mL

View the Complete Stock Solution Preparation Table

* Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator
Dilution Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

This equation is commonly abbreviated as: C₁V₁ = C₂V₂

Concentration _(start)

Volume _(start)

Concentration _(final)

Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 40% PEG300 5% Tween-80 45% Saline
Solubility: ≥ 2.5 mg/mL (7.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.
Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
Protocol 2

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)
Solubility: ≥ 2.5 mg/mL (7.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown).
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
Protocol 3

Add each solvent one by one: 10% DMSO 90% Corn Oil
Solubility: ≥ 2.5 mg/mL (7.05 mM); Clear solution

This protocol yields a clear solution of ≥ 2.5 mg/mL (saturation unknown). If the continuous dosing period exceeds half a month, please choose this protocol carefully.
Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL Corn oil, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage

mg/kg

Animal weight
(per animal)

Dosing volume
(per animal)

μL

Number of animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

DMSO +

Tween-80 +

Saline

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Calculation results:

Working solution concentration: mg/mL

Method for preparing stock solution: mg drug dissolved in μL DMSO (Stock solution concentration: mg/mL).

*In solvent : -80°C, 6 months; -20°C, 1 month (protect from light)

The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).

Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.

If the continuous dosing period exceeds half a month, please choose this protocol carefully.

Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.

Purity & Documentation

Purity: 99.12%

Select Batch:

Data Sheet (274 KB) SDS (393 KB)

COA (247 KB) HNMR (124 KB) RP-HPLC (260 KB) MS (159 KB)

Handling Instructions (2659 KB)

References

[1]. Hyo Jung Kim, et al. Dehydroglyasperin C, a component of liquorice, attenuates proliferation and migration induced by platelet-derived growth factor in human arterial smooth muscle cells. Br J Nutr. 2013 Aug 28;110(3):391-400. [Content Brief]

[2]. Ji Hoon Lee, et al. Dehydroglyasperin C suppresses TPA-induced cell transformation through direct inhibition of MKK4 and PI3K. Mol Carcinog. 2016 May;55(5):552-62. [Content Brief]

[3]. Ji Yeon Seo, et al. Dehydroglyasperin C isolated from licorice caused Nrf2-mediated induction of detoxifying enzymes. J Agric Food Chem. 2010 Feb 10;58(3):1603-8. [Content Brief]

[4]. Seo, J.Y, et al. Protective effects of dehydroglyasperin c against carbon tetrachloride-induced liver damage in mice. Food Sci Biotechnol 23, 547–553 (2014).

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg

DMSO	1 mM	2.8217 mL	14.1084 mL	28.2167 mL	70.5418 mL
	5 mM	0.5643 mL	2.8217 mL	5.6433 mL	14.1084 mL
	10 mM	0.2822 mL	1.4108 mL	2.8217 mL	7.0542 mL
	15 mM	0.1881 mL	0.9406 mL	1.8811 mL	4.7028 mL
	20 mM	0.1411 mL	0.7054 mL	1.4108 mL	3.5271 mL
	25 mM	0.1129 mL	0.5643 mL	1.1287 mL	2.8217 mL
	30 mM	0.0941 mL	0.4703 mL	0.9406 mL	2.3514 mL
	40 mM	0.0705 mL	0.3527 mL	0.7054 mL	1.7635 mL
	50 mM	0.0564 mL	0.2822 mL	0.5643 mL	1.4108 mL
	60 mM	0.0470 mL	0.2351 mL	0.4703 mL	1.1757 mL
	80 mM	0.0353 mL	0.1764 mL	0.3527 mL	0.8818 mL
	100 mM	0.0282 mL	0.1411 mL	0.2822 mL	0.7054 mL